Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA "Cyber" Letters To Take Aim At Domestic Internet Pharmacies

Executive Summary

FDA is in the process of identifying domestic websites that illegally sell prescription drugs online to target in future "cyber" letters warning against the activity.

You may also be interested in...



FDA Budget Adds $45 Mil. For Postmarket Surveillance Efforts In FY 2001

FDA will receive $45 mil. to enhance its postmarketing surveillance system under President Clinton's budget request for fiscal year 2001 released Feb. 7.

FDA Budget Adds $45 Mil. For Postmarket Surveillance Efforts In FY 2001

FDA will receive $45 mil. to enhance its postmarketing surveillance system under President Clinton's budget request for fiscal year 2001 released Feb. 7.

Federal Oversight Of Internet Drug Sales "Disorganized" - Rep. Bliley

House Commerce Committee Chairman Bliley (R-Va.) has given FDA two weeks to fully brief the committee on its role in overseeing the sale of pharmaceuticals over the internet.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS035548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel